July 9 (Reuters) - Bristol-Myers Squibb Co BMY.N :
* ONLY IMMUNO-ONCOLOGY COMBINATION THERAPY APPROVED BY HEALTH CANADA AS FIRST-LINE TREATMENT FOR ADVANCED OR METASTATIC RENAL CELL CARCINOMA
* BRISTOL-MYERS SQUIBB - IMMUNO-ONCOLOGY COMBINATION THERAPY OPDIVO 3MG/KG PLUS YERVOY 1MG/KG FOR INTRAVENOUS INJECTIONS APPROVED BY HEALTH CANADA